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Abstract
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal
adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired
resistance to ERBB2 inhibition. To investigate this question we sought to characterize cell line models of ERBB2-amplified
gastroesophageal adenocarcinoma with acquired resistance to ERBB2 inhibition. We generated lapatinib-resistant (LR)
subclones from an initially lapatinib-sensitive ERBB2-amplified esophageal adenocarcinoma cell line, OE19. We subsequently
performed genomic characterization and functional analyses of resistant subclones with acquired lapatinib resistance. We
identified a novel, acquired SrcE527K mutation in a subset of LR OE19 subclones. Cells with this mutant allele harbour
increased Src phosphorylation. Genetic and pharmacologic inhibition of Src resensitized these subclones to lapatinib.
Biochemically, Src mutations could activate both the phosphatidylinositol 3-kinase and mitogen activated protein kinase
pathways in the lapatinib-treated LR OE19 cells. Ectopic expression of Src E527K mutation also was sufficient to induce
lapatinib resistance in drug-naı¨ve cells. These results indicate that pathologic activation of Src is a potential mechanism of
acquired resistance to ERBB2 inhibition in ERBB2-amplified gastroesophageal cancer. Although Src mutation has not been
described in primary tumor samples, we propose that the Src hyperactivation should be investigated in the settings of
acquired resistance to ERBB2 inhibition in esophageal and gastric adenocarcinoma.
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Introduction
Gastroesophageal (GE) adenocarcinomas are one of the leading
causes of the cancer death worldwide [1]. The mainstay of
systemic chemotherapy for patients with advanced or metastatic
disease still consists of cytotoxic agents including fluoropyrimi-
dines, platinum derivatives, taxanes and topoisomerase inhibitors
[2–5]. However, a recent randomised trial demonstrated that
trastuzumab, a humanized IgG1 monoclonal antibody targeting
human epidermal growth factor receptor-2 (ERBB2 or HER2),
improved overall survival by 2.7 months in patients with ERBB2-
amplified advanced gastroesophageal cancer when combined with
chemotherapy [6]. Based upon these results, trastuzumab is now a
routine component of care for patients with metastatic ERBB2-
amplified GE adenocarcinomas.
Despite the adoption of ERBB2 inhibitor therapy in clinical
practice, the addition of anti-HER2 targeting strategies in patients
with ERBB2 amplified gastroesophageal cancer have been
modest, attributable both to intrinsic resistance of many tumors
to trastuzumab containing therapy as well as to the emergence of
acquired resistance in those tumors which initially responded to
treatment. The etiology of resistance to ERBB2-directed therapies
has been widely investigated in breast cancer [7–15]; the accepted
resistance mechanisms included constitutive activation of the PI3-
K pathway [7,9], truncated p95 isoform of HER2 receptor which
cannot bind to trastuzumab [15], and constitutive Src activation as
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a common node downstream of multiple pathways [10]. In GE
cancer, the variant of dopamine and cyclic AMP-regulated
phosphoprotein (t-DARPP) has been suggested as a resistance
mechanism to ERBB2 inhibitors [16], and exogenous HGF
administration to cell line cultures has been shown to induce
in vitro resistance in GE adenocarcinoma [17]. In one report,
NCI-N87 ERBB2-amplified gastric adenocarcinoma cells were
found to acquire enhanced activity of Src activity following
prolonged in vitro exposure to trastuzumab [18]. Beyond these
reports, there is little understanding the etiology of acquired or de
novo resistance to ERBB2 inhibition in GE cancer.
To address this problem, various clinical efforts are evaluating
the empiric potential of distinct second-line agents to improve
survival and clinical responses [19–22]. To guide the development
of such treatment strategies, we sought to investigate the potential
mechanisms of acquired resistance to ERBB2 inhibition in
ERBB2-amplified GE adenocarcinoma cell line models. Indeed,
in other tumor types, study of means of resistance in cell line
models has identified resistance mechanisms subsequently validat-
ed in primary cancers [9,10,14]. Although trastuzumab is utilized
in clinical practice, trastuzumab has limited efficacy in in vitro
culture compared to direct kinase inhibitors such as lapatinib
[23,24]. Therefore, we have chosen lapatinib as our tool
compound to identify mechanisms by which ERBB2-amplified
GE adenocarcinomas can bypass effective ERBB2 inhibition.
From the originally lapatinib-sensitive ERBB2-amplified esoph-
ageal adenocarcinoma cell, OE19, we generated several resistant
subclones by prolonged exposure to lapatinib. Through genomic
and functional analyses of this lapatinib-resistant model, we found
that an activating mutation of Src was responsible for the acquired
lapatinib resistance in OE19 cells. In addition, we further
demonstrated that genetic or pharmacologic blockade of Src
could restore ERBB2 inhibitor sensitivity in lapatinib-resistant
cells. These data establish the role of oncogene Src as a
pharmacologically tractable candidate mediator of acquired
lapatinib resistance in ERBB2-positive GE adenocarcinomas.
Materials and Methods
Cell lines and Reagents
OE19 cells were obtained from the European Collection of Cell
Cultures (ECACC), and OE33 cells were purchased from the
Sigma (St. Louis, MO). OE19 is ERBB2-amplified gastroesoph-
ageal cancer cell line and sensitive to lapatinib, hence OE33 is
ERBB2- and MET-amplified gastroesophageal cancer cell line
and has intrinsic resistance to lapatinib. OE19 and OE33 were
cultured in a humidified, 5% CO2 atmosphere at 37uC in Roswell
Park Memorial Institute (RPMI-1640; GIBCO BRL, Grand
Island, NY) medium supplemented with 10% fetal bovine serum.
Tyrosine kinase inhibitors (lapatinib, saracatinib, and crizotinib)
were purchased from the LC laboratories and were dissolved in
dimethylsulfoxide (DMSO). Trastuzumab was purchased from the
Department of Pharmacy at the Dana-Farber Cancer Institute.
Generation of Lapatinib-Resistant (LR) Subclones
Working with lapatinib-sensitive ERBB2-amplified esophageal
adenocarcinoma cell line, OE19, whose IC50 to lapatinib is
200 nM, we initiated the development of lapatinib resistance by
culturing the cell line in the presence of progressively increasing
doses of lapatinib during three months; the final concentration of
lapatinib was 3 mM and some clones survived at a low density with
small colonies. Following six months of culture with drug, we were
able to obtain OE19 derivatives that were capable of proliferation
in the presence of 3 mM of lapatinib. We could observe that
several colonies had distinct cellular morphologies at this time, and
the pathologist (JK) picked some colonies with distinct morphol-
ogies and named them according to the selecting orders. We
subsequently expanded distinct clonal subcultures from the
resistant OE19 cells and subsequently extracted DNA from seven
distinct clonal populations for genomic analysis.
Genomic DNA extraction and Targeted Exome
sequencing
Genomic DNA was extracted from the parental OE19 and
isolated LR subclones using DNeasy Blood & Tissue Kit (Qiagen)
per manufacturer’s protocol. DNA quality was evaluated by
quantification using Quant-iT Pico Green dsDNAassay Kit
(Invitrogen) per manufacturer’s protocol. DNA from these
resistance cell lines (and the parental OE19) were subjected to
focused exon sequencing using the Oncopanel_v2 cancer gene
panel at the Center for Cancer Genome Discovery at the Dana-
Farber Cancer Institute. OncoPanel_v2 represents a targeted
sequencing strategy to simultaneously detect mutations, translo-
cations and copy-number variations in archived clinical tumor
specimens. Targeted sequencing was achieved by designing RNA
baits to capture the exons of 504 genes with relevance to cancer.
Sequencing libraries were prepared, as previously described
[25], starting from 100 ng of genomic DNA. Libraries were
quantified by QPCR (Kapa Biosystems, Inc., Woburn, MA) and
pooled in equimolar concentrations to 500 ng total and enriched
for the Oncopanel_v2 baitset using the Agilent SureSelect hybrid
capture kit. The enriched targeted exon libraries were again
quantified by QPCR (Kapa Biosystems, Inc., Woburn, MA)
subsequently sequenced in one lane of a Hiseq2000 sequencer
(Illumina Inc., San Diego, CA) in a 26 100 bp pair-end mode.
Sequence alignment, demultiplexing and variant calling, including
SNV and Indels, was performed using PICARD, GATK tools,
Mutect and IndeLocator as previously described [25]. Sequence
results from the resistance subclones were compared to the
genomic results from the parental OE19 cell line in order to
identify putative somatic mutations and copy-number aberrations
that are the potential etiology of resistance. Only candidate
somatic alterations with mutant allele fractions .5% were
considered.
Direct DNA Sequencing Analysis
The Src E527K mutation (g1579a) was additionally validated by
direct sequencing as follows; Src was PCR-amplified from genomic
DNA using a 2720 thermal cycler (Applied Biosystems) using
OneTaq Quick-Load 2X mix (BioLabs) with each primer
(forward: 59- GGGATGGTGAACCGCGAGGT-39, reverse: 59-
TTCTCCCCGGGCTGGT-39). DNA electrophoresis was per-
formed and the pure amplified PCR product with 203 bp size was
isolated using QIAquick Gel Extraction Kit (Qiagen) per
manufacturer’s protocol. We performed TA cloning with purified
PCR products using TOPO TA Cloning Kit, bacterial transfor-
mation and propagation with competent E.coli, and extracted
plasmid which contained sequence target using QIAprep Mini-
prep Kit (Qiagen). Direct sequencing was using the M13R
sequencing primer at Genewiz, Inc.
DNA Restriction Analysis
We performed DNA restriction analysis to confirm that the Src
E527K mutation is an acquired event owing to the prolonged
lapatinib exposure, and it is not already present in the parental
OE19 cells. Genomic DNA were extracted from the parental
OE19 and two LR subclones harbouring Src mutant, and PCR-
Src Mutants and Lapatinib Resistance
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amplified as described above. Genomic DNA from the Het1A
cells, a non-tumor esophageal cell line, was also tested as a
negative control.
Aliquots from the PCR amplicons were digested separately with
Ban II restriction enzyme (New England Biolabs Inc., Beverly,
USA) at 37uC for 4 hours. Digestions were carried out per
manufacturer’s protocol.
DNA restriction fragments were electrophoresed on 2.0%
agarose gels with ethidium bromide (0.5 mg/mL). DNA fragment
sizes were estimated through comparison with EZ Load 100 bp
Molecular Ruler (Bio-Rad).
Vectors and Lentiviral Infection
Lentiviruses were produced by transfecting 293T cells with
FuGENE6 transfection reagent (Promega) with 300 ng of VSVG,
2.7 mg of delta-8.9 or PSPAX2 and 3 mg of each construct. Target
cells were infected with each virus in the presence of polybrene
(8 mg/ml) for 6 hours. Forty-two hours later, the infected target
cells were selected by using a predefined concentration of
puromycin (1.5 mg/ml for OE33, and 2.0 mg/ml for OE19) at
least for 7 days before biological experiments.
pLKO-shSrc vectors were obtained from The RNAi Consor-
tium, and the shRNA sequences targeting Src were as following;
for shSrc1 (NM_198291.1, clone ID: TRCN0000038149), 59-
CCGGGACAGACCTGTCCTTCAAGAACTCGAGTTCTT-
GAAGGACAGGTCTGTCTTTTTG-39; for shSrc2
(NM_198291.1, clone ID: TRCN0000038151), 59-
CCGGGTCATGAAGAAGCTGAGGCATCTCAGATGCCT-
CAGCTTCTTCATGACTTTTTG-39. pLKO-shLacZ1650
served as control in the RNAi silencing experiments.
Wild-type pDONR223-Src (#23934) was purchased from
Addgene Inc. (Cambridge, Massachusetts). pDONR223-Src
E527K was made by site-directed mutagenesis using QuikChange
II XL Site-Directed Mutagenesis Kit from Agilent Technologies,
Inc. (Santa Clara, California). Primer sequences for site-directed
mutagenesis (g1579a) were following; sense 59-ACTTCACGTC-
CACCAAGCCCCAGTACCAG-39 and antisense 59-
CTGGTATGGGGCTTGGTGGACGTGAAGT-39. pLX301-
Src wild-type and PLX301-Src E527K lentiviral vectors were made
from pDONR223-Src wild-type and pDONR223–Src E527K,
respectively, by performing LR clonase reaction with pLX301
destination vector (Invitrogen). pLX301-GFP served as a control
in the ectopic expression experiments.
In vitro cell proliferation assay
Cells (4,000/well) were seeded in quadruplicate in 96-well plate,
were treated with either vehicle or variable doses of small molecule
inhibitors after 24 hours, and then were allowed to grow for
72 hours. For cells grown in trastuzumab, cells were allowed to
proliferate for five days prior to assays of cell proliferation. We
used Cell-titer Glo assay (Promega, Madison, Wisconsin) to
measure cell viability. Percentage of inhibition of cell proliferation
was calculated as [1-(treated cells/untreated cells) 6 100]. The
results from the cell viability assay were compared between cell
lines using repeated measures analysis of variance (ANOVA) and
also were tested using student t-test at the specific concentration. A
p value ,0.05 was considered statistically significant.
Immunoblotting
Cells were lysed with RIPA lysis buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium
deoxycholate) supplemented by protease inhibitor cocktail (Roche)
and phosphatase inhibitor cocktails (Calbiochem). Lysates were
separated on 7.5% or 8% Tris-Glycine SDS-polyacrylamide gel
and were transferred to PVDF membranes (Millipore). The
membranes were blocked with 5% skim milk (Bio-Rad) dissolved
in TBST buffer (50 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-
20). Then, the membranes were incubated with primary
antibodies overnight at 4uC. Anti-EGFR antibody (#A300-
388A) was purchased from Bethyl Laboratories. Anti-b-actin
antibody (#A5441) and anti-c-tubulin antibody (#A9044) were
purchased from Sigma-Aldrich. All other antibodies including
anti-phospho EGFR Y1068 (#3777), anti-phospho ERBB2
Y1221/1222 (#2243), anti-ERBB2 (#2165), anti-phospho SRC
Y416 (#6943), anti-SRC (#2109), anti-phospho-ERK 1/2 T202/
Y204 (#4370), anti-ERK 1/2 (#4695), anti-phospho AKT S473
(#4060), and anti-AKT (#9272) were purchased from Cell
Signaling Technologies. Horseradish peroxidase-conjugated sec-
ondary antibodies (anti-rabbit: #31460, anti-mouse: #31430,
Pierce) and SuperSignal West Pico Chemiluminescent Substrate
(Pierce) were used to detect signals.
Results
The Novel Src E527K mutation was found in the two
lapatinib-resistant (LR) OE19 subclones
For generating lapatinib-resistant subclones, OE19 cells were
treated with lapatinib, of which dose was progressively increased
from 200 nM to 3 mM during 3 months. We expanded the
surviving clones in the presence of 3 mM of lapatinib till 6 months
and colonies with distinct cellular morphologies were selected.
Each selected colony was subcultured in the different plates in the
presence of 3 mM of lapatinib, and 7 subclones were selected for
genomic analysis (Figure 1A).
Using DNA from these seven subclones as well as from the
parental OE19 cell population, we attempted to identify acquired
genomic alterations that could have induced drug resistance. DNA
from these distinct populations were submitted for a focused next-
generation sequencing panel wherein the coding exons from 504
distinct genes were isolated via solution hybrid capture and then
sequenced with an Illumina sequencer with an average depth of
252.56 and 97.1% of targets achieving a minimum coverage of
306 (Table S1). These DNA samples were analysed for the
presence of somatic mutations and copy-number alterations
unique to the resistance subclones compared to the parental cell
line. Across these LR subclones, we identified distinct somatic
mutations affecting genes Src, KEAP1 and PHOX2B (Figure 1A).
We did not find any evidence for the mutations found in the
derived mutants described as above in the parental OE19 cell line
of which sequencing coverage for the Src 527 codon of 306.
Within these data we initially focused upon two distinct clones,
both harbouring the same acquired Src E527K mutation (Fig-
ure 1B) which was present in,30% of sequenced alleles in each of
these two subclones. In the setting of arm-level gain of 20q in
OE19 cells, a 30% allele fraction of this mutation is consistent with
one of the three copies of Src in the cell line being mutated clonally
in this population. Notably, this specific base change, an E to K
substitution at codon 527, had been utilized as a means to
artificially activate Src in previous biochemical studies of this
kinase [10]. Comparing the two clones with the Src mutation, we
noted that one of the clones harboured a unique KEAP1 mutation
suggesting that these two Src-mutant clones may not be identical.
Review of the copy-number spectrum between these two Src-
mutant subclones, however, revealed a similar spectrum of copy-
number aberrations (Figure S1) suggesting that the two clones may
have diverged from a common ancestor prior to the KEAP1 event
in one subclone. Given the likely shared origin, we termed these
Src Mutants and Lapatinib Resistance
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Figure 1. Generation of lapatinib-resistant (LR) OE19 subclones, and the identification of a novel, acquired SrcE527K mutation. A,
Schematic view of the development of lapatinib resistance OE19 cells followed by subcloning of distinct clones of resistant cells for genomic
characterization. At right is the listing of somatic alterations identified in the distinct subclones, compared to the genome of the parental OE19 cells.
The allelic fraction of each mutation, percent of sequenced reads with the mutant allele, is listed for each candidate mutation. B, IGV (Integrated
Genomic Viewer) snapshot of Src mutations in two LR subclones compared to the sequencing seen from this locus in the parental, lapatinib-sensitive
cell line. C, Direct sequencing results from genomic DNA from both parental OE19 cells and Src E527K mutant LR2A and LR2B subclones identifies
mutation detected from next-generation sequencing. D, DNA restriction analysis results using Ban II enzyme, from the genomic DNA from the
Src Mutants and Lapatinib Resistance
PLOS ONE | www.plosone.org 4 October 2014 | Volume 9 | Issue 10 | e109440
clones lapatinib-resistant (LR) clones LR2A and LR2B. Src E527K
mutation was confirmed by direct sequencing (Figure 1C).
Although we did not identify this Src mutation in the parental
cell line from our sequencing, we performed additional focused
analysis of this locus to detect if low-frequency Src mutant cells
were present in the parent cell population. To identify possible
mutations at low frequency, we performed restriction enzyme
digestion of PCR-amplified DNA from the parental OE19, LR2A,
LR2B, and Het1A using Ban II restriction enzyme. The target
sequence of Ban II restriction enzyme is G(A/G)GC(T/C)C,
which will cut wild-type Src sequence. The PCR amplicons of
203 bp from two LR subclones harboring Src mutant were not
digested, in contrast those from the parental OE19 and Het1A
were totally digested and yielded 182 bp products (Figure 1D).
From these results, we could identify no evidence of the Src E527K
mutant in the parental cell population, suggesting it is an acquired
event during the prolonged lapatinib exposure.
LR2A and LR2B subclones showed stable resistance to
lapatinib
With these two Src-mutant subclones, we re-evaluated their
lapatinib sensitivity (Figure 2A). Each of these two subclones had
an IC50 value for lapatinib greater than 1,000 nM, far exceeding
that of the parental cell line. We also evaluated these two Src-
mutant subclones for their sensitivity to trastuzumab, and they
showed reduced growth inhibition to trastuzumab compared to
the parental OE19 cells (Figure S2).
Acquired Src E527K mutation is an activating mutation
To investigate the function of mutant Src within the LR2A and
LR2B clones, we evaluated first Src phosphorylation at tyrosine
416, a marker of the kinase’s represent an active status [26] with
immunoblotting. Both the LR2A and 2B subclones showed higher
phosphorylation of Src compared to the parental OE19 cells
(Figure 2B) consistent with what we would predict in the setting of
an activating mutation. Additionally, in both the LR2A and LR2B
clones, the expression and phosphorylation of ERBB2 and EGFR
was slightly decreased relative to the parental cell line in the
absence of lapatinib.
RNAi-mediated silencing of Src sensitizes Src mutant
OE19 cells to lapatinib
Given the clear association between Src mutation and lapatinib
resistance, we asked whether shRNA-mediated silencing of Src
might restore lapatinib sensitivity in LR2A and LR2B clones.
Indeed, silencing of Src by two independent small hairpin
constructs sensitized both LR2A and LR2B clones to lapatinib
treatment to the extent that the sensitivity profile of those two LR
subclones became similar to that of parental OE19 (Figure 3A).
Mock or control hairpin transduction did not impact the lapatinib
sensitivity of all cell lines (Figure 3A–B).
Consistent with lapatinib resistance profile, we observed
sustained p-ERK 1/2 phosphorylation even in the presence of
1 mM lapatinib in mock- or control hairpin-transduced LR2A and
LR2B subclones. Notably, the p-ERK 1/2 phosphorylation was
successfully blocked by lapatinib treatment in shSrc transduced
parental OE19, Src E527K mutant LR2A and LR2B subclones, and Het1A (normal esophageal cell line). Ban II enzyme cuts and yields new amplicons of
182 bp in the parental OE19 and Het1A, however, the bands of 203 bp, which contained Src mutants, are still visualized in the two Src mutant
subclones, LR2A and LR2B.
doi:10.1371/journal.pone.0109440.g001
Figure 2. Comparisons of lapatinib sensitivities and the baseline signalling proteins activities between parental and lapatinib-
resistant subclones. A, Lapatinib sensitivity curves in the parental OE19 and two lapatinib-resistant (LR) subclones. The calculated values of IC50 of
lapatinib were 200 nM in parental cells and .1,000 nM in two LR subclones. Values were presented as relative cellular viability relative to vehicle-
treated controls with the mean 6 S.E. of quadruplicate from a representative experiment. The p values were ,0.0001 for OE19 vs LR2A and OE19 vs
LR2B, and was 0.129 for LR2A vs LR2B. The p values were calculated by two-way ANOVA. B, Immunoblots showing the phosphorylations of distinct
signalling molecules in parental OE19 cells and the Src-mutant lapatinib-resistant derivatives.
doi:10.1371/journal.pone.0109440.g002
Src Mutants and Lapatinib Resistance
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LR subclones (Figure 3C). These data indicate that, in these Src-
mutant LR subclones, blockade of both Src and ERBB2 is
required to completely block pathologic mitogenic signalling. The
phosphorylations of AKT and ERK were slightly downregulated
Figure 3. Effects of RNAi-mediated silencing of Src on lapatinib sensitivities and responses of signalling proteins. A, Lapatinib
sensitivity curves for LR2A and LR2B subclones transduced with shSrc or control (shLacZ). The lapatinib sensitivities were restored after RNAi silencing
of Src in the two LR subclones. The calculated values of IC50 were following; 200 nM for parental OE19; .1,000 nM for LR2A
Mock, LR2A shLacZ, LR2B
Mock, and LR2B shLacZ; 432.8 nM and 403.7 nM for LR2A shSrc1 and LR2A shSrc2, respectively; 276.6 nM and444.2 nM for LR2B shSrc1 and LR2B shSrc2,
respectively. Values were presented as relative cellular viability relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from a
representative experiment. In the lapatinib sensitivity curve for LR2A and its subclones transduced with lentiviral vectors, the p value was 0.121 for
mock vs control (shLacZ), ,0.0001 for control vs shSrc1, and ,0.0001 for control vs shSrc2. In the lapatinib sensitivity curve for LR2B and its subclones
transduced with lentiviral vectors, the p value was 0.764 for mock vs control, ,0.0001 for control vs shScr1, and 0.012 for control vs shSrc2. The p
values were calculated by two-way ANOVA. B, Relative cell viability after 1 mM concentration of lapatinib treatment in two LR subclones with or
without RNAi-mediated silencing of Src. The p values were calculated by two-tailed t-test. LR subclones transduced with shSRC restored lapatinib
sensitivities. Values were presented as relative cellular viability relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from a
representative experiment. C, Immunoblots showing changes of various signalling proteins after treatment with 1 mM concentration of lapatinib in
two LR subclones with or without RNAi-mediated silencing of Src. Proteins were harvested 4 hours after lapatinib or vehicle treatment. D, Lapatinib
sensitivity in OE33 cells following regarding RNAi transduction targeting Src. Values were presented as relative cellular viability relative to vehicle-
treated controls with the mean 6 S.E. of quadruplicate from a representative experiment. Proteins were harvested 4 hours after lapatinib or vehicle
treatment. There was no statistical significance between cell lines in terms of lapatinib sensitivity (0.070 for mock vs control [shLacZ], 0.520 for control
vs shSrc1, and 0.753 for control vs shSrc2, respectively). The p values were calculated by two-way ANOVA.
doi:10.1371/journal.pone.0109440.g003
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in the shLacZ transduced LR subclones, which were not observed
dominantly in the mock-treated LR subclones, possibly attribut-
able to the effects from lentiviral infections and puromycin
selection. As an additional control to ensure that these Src-directed
shRNA vectors did not impact lapatinib sensitivity due to non-
specific off target effects, we also evaluated the impact of these
constructs on the lapatinib sensitivity of OE33 cell line which is not
sensitive to lapatinib through unrelated mechanism, MET co-
amplification. In this model, introduction of the shSrc did not
sensitize OE33 cells to lapatinib (Figure 3D).
Lapatinib resistance could be overcome by combination
treatment with saracatinib
We then tested whether pharmacologic inhibition of Src by
saracatinib in LR2A and LR2B subclones could restore lapatinib
sensitivity. Saracatinib is a dual tyrosine kinase inhibitor targeting
c-Src/Abl kinase. Saracatinib showed preclinical activity in
various cancer cell lines including gastroesophageal cancers [27–
34]; however, only low to modest antitumor activity were
demonstrated in several phase I or II clinical trials when tested
as monotherapy [35–38].
While the two Src E527K mutant subclones were not sensitive to
either lapatinib or saracatinib alone, their growth was effectively
inhibited when the two drugs were combined (Figure 4A & 4B).
Consistent with this drug sensitivity profile, AKT and ERK
phosphorylation was sustained when the LR subclones were
treated with either lapatinib or saracatinib alone, and their
sustained phosphorylation was blocked upon the combined
treatment of both drugs (Figure 4C). HER2 and EGFR phos-
phorylations were blocked upon lapatinib treatment regardless of
the presence of saracatinib in both the parental OE19 cells and the
two LR subclones suggesting that the mutant Src-mediated
resistance is independent of HER2 or EGFR signalling (Fig-
ure 4C). These data suggest that pathologic Src activation
enhances survival of lapatinib resistant clones upon ERBB2
inhibition through activation of both PI3-K and MAPK pathways.
Saracatinib alone could not inhibit cellular proliferation either in
the parental or in the two LR subclones (Figure S3). In MET co-
amplified OE33 cells, saracatinib treatment did not show any
synergy with lapatinib treatment. By contrast, the addition of
MET inhibitor crizotinib synergistically inhibited cell proliferation
(Figure 4D).
Ectopic expression of Src E527K induces lapatinib
resistance in the parental OE19 cells
Last we evaluated the ability of exogenous expression of the Src-
mutants to impact the lapatinib sensitivity of OE19 cells. We
generated the Src E527K plasmid using site-directed mutagenesis,
and transduced either wild-type Src, mutant Src or GFP control
into parental OE19 cells. Indeed, Src E527K transduced OE19
developed lapatinib resistance (IC50 to the lapatinib, 1179.0 nM),
while GFP or Src wild-type transduced OE19 remained sensitive to
lapatinib (IC50 to the lapatinib, 256.6 nM and 313.8 nM,
respectively, Figure 5A). Furthermore, the lapatinib resistance
conferred by exogenous expression of Src E527K was overcome by
the combined treatment of saracatinib (Figure 5B). Saracatinib
also reversed the mild lapatinib resistance induced by the wild-type
Src transduction.
As in the LR subclones harbouring spontaneous Src mutation,
expression of p-Src was increased in Src transduced OE19 either
with wild-type or E527K mutant compared to the parental or GFP
transduced cells (Figure 5C). Src E527K transduced OE19 showed
particularly high expression of p-SRC. Although the phosphory-
lation of Src in the OE19 cells transduced with wild-type Src was
not effectively inhibited by saracatinib, Src phosphorylation in Src
E527K transduced OE19 was significantly inhibited by saracatinib
regardless of the presence of lapatinib. Additionally, the levels of p-
AKT and p-ERK 1/2 were not suppressed by lapatinib alone in
the Src E527K transduced OE19, consistent with our hypothesis
that constitutive Src activation might sustain both downstream
signalling pathways. However, phosphorylation of both AKT and
ERK 1/2 was inhibited with combination of saracatinib and
lapatinib, paralleling the results from cells with spontaneously
acquired Src mutant. Taken together, pathologic Src activation
could induce lapatinib resistance in ERBB2-amplified GE
adenocarcinoma and the resistance could be reversed by the
additional Src inhibition.
Discussion
As an effort to model acquired resistance of ERBB2-amplified
GE adenocarcinomas to ERBB2 inhibition, we generated
lapatinib-resistant subclones from an initially lapatinib-sensitive
ERBB2-amplified esophageal adenocarcinoma cell line by pro-
longed exposure to the inhibitor. Through genomic and functional
analysis of LR subclones, we found that an activating mutation of
Src was responsible for the acquired lapatinib resistance in two of
seven isolated subclones in this in vitro model system. In addition,
we further demonstrated that genetic or pharmacologic blockade
of Src could restore ERBB2 inhibitor sensitivity in LR subclones
with hyperactive Src. Although our data remain to be validated in
patient samples, these data establish the role of oncogene Src as a
pharmacologically tractable candidate mediator of acquired
lapatinib resistance in ERBB2-expressed GE adenocarcinomas.
Recently, increased Src kinase activity was suggested as one of
the resistance mechanisms to both trastuzumab and lapatinib in
breast cancer cell lines [10,39]. c-Src is a membrane-associated
tyrosine kinase and cellular homologue of the oncogenic v-Src
encoded by the chicken Rous sarcoma virus [40]. Src acts as a
common signalling node by interacting with multiple receptor
tyrosine kinases [10,29,41]. In breast cancer, Zhang et al
demonstrated that increased Src kinase activity was responsible
for both the de novo and acquired trastuzumab resistances.
Separate investigators demonstrated that lapatinib-resistant
SKBR3 breast cancer cells showed increased activity of Src
kinases and persistent levels of activation of ERK 1/2 and AKT
and that treatment with saracatinib reduced AKT and ERK 1/2
activity and restored lapatinib sensitivity [39]. A recent study by
Han et al. similarly reported that increased Src activity was
observed in the trastuzumab-resistant ERBB2-amplified GE
cancer cell line, NCI-N87, and showed that trastuzumab and
saracatinib synergistically inhibited the in vitro growth of both
parental and trastuzumab-resistant NCI-N87 [18]. We also have
generated lapatinib-resistant subclones from the NCI-N87 cell
line, and performed similar sequencing in those subclones;
however, we could not identify any similar Src mutations (data
not shown). Ongoing efforts are trying to identify alternative
etiology of resistance mechanisms in these lapatinib-resistant NCI-
N87 subclones. Although the role of increased Src activity in the
resistance of ERBB2-amplified breast cancer and GE cancer to
ERBB2 inhibition has been documented, we reported here, for the
first time, the activation of a spontaneous Src mutation after
prolonged exposure to HER2 inhibitor could induce lapatinib
resistance in ERBB2-amplified GE adenocarcinoma and present
the first evidence of acquired mutation of Src as an etiology of
resistance. While these data clearly demonstrate the capacity of
activated Src to serve as a mediator of acquired resistance to
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ERBB2 inhibitor therapy in GE cancers, future studies will be
required to query the presence of Src mutation or enhanced
activity of this kinase in patient samples upon emergence of
resistance.
Additionally, future studies will need to address potential
differences between mechanisms of acquired resistance to small
molecule compared to antibody ERBB2 inhibitors in GE
adenocarcinomas. However, mechanisms for acquired resistance
to trastuzumab have been reported to be similar to those to
lapatinib in the breast cancer field. Mechanisms for de novo or
acquired trastuzumab resistance included constitutive activation
PI3-K pathway owing to PTEN deficiency or PIK3CA gene
mutation [9,42], the expression of truncated HER2 receptors [15],
and overexpressions of other receptor tyrosine kinases which
include EGFR, insulin-like growth factor-1 receptor, and hepato-
cyte growth factor receptor [43–45]. Mechanisms for lapatinib
resistance were generally similar to those with the trastuzumab
resistance [46–49].
Saracatinib, the c-Src/Abl dual targeting inhibitor, has shown
only mild to moderate antitumor activity in phase I/II clinical
Figure 4. Effects of pharmacologic inhibition of Src using saracatinib in combination with lapatinib in LR subclones. A, Dose-response
curves from escalated dose of lapatinib in the presence of 1 mM concentration of saracatinib. The calculated values of IC50 for lapatinib were
following; 207.3 nM and 145 nM, respectively, after lapatinib alone and in the presence of saracatinib for parental OE19; .1,000 nM after lapatinib
alone for LR2A and LR2B; 91.66 nM and 224.0 nM in the presence of saracatinib in LR2A and LR2B, respectively. Values were presented as relative
cellular viability relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from a representative experiment. The p values calculated
by two-way ANOVA were ,0.0001 comparing lapatinib alone with lapatinib plus saracatinib both in the LR2A and LR2B. B, Relative cell viability in the
parental OE19 and two LR subclones after 1 mM concentration of saracatinib or lapatinib, either alone or combination. The p values were calculated
by two-tailed t-test. Values were presented as relative cellular viability relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from
a representative experiment. C, Immunoblots showing changes of in intracellular signalling proteins after treatment with 1 mM concentration of
lapatinib or saracatinib, either alone or combination, in LR subclones. Proteins were harvested 4 hours after each treatment. D, Relative cell viability
in the OE33, ERBB2 and MET co-amplified gastroesophageal cancer cells, after treatment with various drugs either alone or combination. The effect of
combination treatment with lapatinib and saracatinib did not differ either from lapatinib alone or saracatinib alone; the combination treatment with
lapatinib and crizotinib, which is a potent MET inhibitor, showed synergistic effects. The p values were calculated by two-tailed t-test. Values were
presented as relative cellular viability relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from a representative experiment.
doi:10.1371/journal.pone.0109440.g004
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trials [35–38]. However, these trials did not utilize genomic or
biochemical biomarkers to guide enrolment nor did it investigate
the situation of ERBB2 inhibitor insensitivity. Based upon the
results presented in this study, further focused evaluation of Src
activation, either due to mutation or other means of activation,
should be considered on patient tumors following the acquisition
of resistance to ERBB2-directed therapy for evidence. Such testing
should evaluate for both activation due to mutation or from other
mechanisms. Should such Src activation or Src mutation be
identified in such tumor samples, the results from this report
support subsequent efforts to perform clinical trials of a
combination of ERBB2 inhibition and Src inhibition. Such
therapy may be able to lead to meaningful improvements in
outcomes for patients whose tumors utilize Src activation as a
means of bypassing ERBB2 inhibition.
Supporting Information
Figure S1 Inferred copy-number plots for LR sub-
clones. Comparison of the copy-number profiles of the two
Src-mutant LR subclones following normalization against the
parental, lapatinib-sensitive OE19 cell line (x-axis: arbitrary
chromosomal co-ordinates, color codes represent each chromo-
some in increasing order, y-axis: inferred copy-number).
(TIFF)
Figure S2 Growth inhibition curves in the Two Src-
mutant LR subclones after increasing dose of trastuzu-
mab. Values were presented as relative cellular viability relative
to vehicle-treated controls with the mean 6 S.E. of quadruplicate
from a representative experiment. The p values calculated by two-
way ANOVA were ,0.0001 both in the comparisons of viabilities
of OE19 vs LR2A and OE19 vs LR2B.
Figure 5. Impact of ectopic expression of SrcE527K in parental OE19 on lapatinib sensitivity and cell signalling. A, Dose-response curves
for lapatinib in the non-transduced parental OE19 (OE19 Mock), transduced with GFP (OE19 GFP), wild-type Src (OE19 Src wild-type) or Src E527K mutation
(OE19 Src E527K). The calculated values of IC50 for lapatinib was .1,000 nM in OE19
Src E527K cells. Values were presented as relative cellular viability
relative to vehicle-treated controls with the mean 6 S.E. of quadruplicate from a representative experiment. The p value calculated by two-way
ANOVA was 0.376 for mock vs control (GFP), ,0.0001 for control vs wild-type Src, and ,0.0001 for control vs Src E527K. B, Relative cell viability
lapatinib in the non-transduced parental OE19 (OE19 Mock), transduced with GFP (OE19 GFP), wild-type Src (OE19 Src wild-type) or Src E527K mutation
(OE19 Src E527K). The p values were calculated by two-tailed t-test. Values were presented as relative cellular viability relative to vehicle-treated controls
with the mean 6 S.E. of quadruplicate from a representative experiment. C, Immunoblots showing changes of various signalling proteins after
treatment with 1 mM concentration of lapatinib or saracatinib, either alone or combination, in the OE19 cells with or without Src E527K transduction.
doi:10.1371/journal.pone.0109440.g005
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(TIFF)
Figure S3 Growth inhibition curves in the parental
OE19 and in the two Src-mutant LR subclones after
increasing dose of saracatinib. Values were presented as
relative cellular viability relative to vehicle-treated controls with
the mean 6 S.E. of quadruplicate from a representative
experiment. There was no statistical significance in terms of cell
viability between cell lines.
(TIFF)
Table S1 Next-generation sequencing panel in 8 cell lines
including parental OE19 and 7 lapatinib-resistant subclones.
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